Pliant Therapeutics Inc

$30.26 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Join the waitlist

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis. It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-ß). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of avß6 and avß1. The Company’s second clinical-stage product candidate, PLN-1474, is a small-molecule, selective inhibitor of avß1 in development for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.

Stock Analysis

last close $36.56
1-mo return 6.4%
3-mo return 33.3%
avg daily vol. 283.51T
52-week high 43.92
52-week low 19.43
market cap. $1.3B
forward pe -
annual div. -
roe -40.2%
ltg forecast -
dividend yield -
annual rev. $42M
inst own. 80.3%

Join the waitlist for early access and a chance to earn $50 in free stock

Join the waitlist